Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock
Stocks
6990
CNE1000062J1
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 516.50 HKD | +8.74% |
|
+3.51% | +31.69% |
| 08/07 | Sichuan Kelun-Biotech Seeks HK$2.7 Billion via Share Placement | MT |
| 01/07 | Sichuan Kelun-Biotech Subscribes to Wealth Management Products | MT |
| Market Cap | 107B 123B 15.75B 13.77B 12.7B 11.73B 22.26B 1,502B 22.64B 152B 59.61B 740B 59.12B 57.84B 2,543B | P/E 2026 * |
-539x | P/E 2027 * | 165x |
|---|---|---|---|---|---|
| Enterprise Value | 104B 120B 15.29B 13.37B 12.34B 11.39B 21.62B 1,458B 21.98B 147B 57.88B 718B 57.41B 56.16B 2,470B | EV / Sales 2026 * |
38x | EV / Sales 2027 * | 22.6x |
| Free-Float |
52.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
| 1 day | +8.74% | ||
| 1 week | +3.51% | ||
| Current month | +18.41% | ||
| 1 month | +30.96% | ||
| 3 months | +4.77% | ||
| 6 months | +8.42% | ||
| Current year | +31.69% |
| 1 week | 462.6 |  | 539 |
| 1 month | 386.4 | | 539 |
| Current year | 339.6 | | 539 |
| 1 year | 329.8 | | 581 |
| 3 years | 62 | | 581 |
| 5 years | 60.6 | | 581 |
| 10 years | 60.6 | | 581 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jun You Ge
CEO | Chief Executive Officer | 54 | 01/03/2022 |
Ze Jian Zhou
DFI | Director of Finance/CFO | 43 | 17/08/2022 |
Xiang Yang Tan
CTO | Chief Tech/Sci/R&D Officer | 63 | 05/07/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
CHM | Chairman | 75 | 01/03/2022 |
Jin Ping Jin
BRD | Director/Board Member | 54 | 15/02/2023 |
Yue Dong Li
BRD | Director/Board Member | 49 | 15/02/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 30/06 | Other | Director | -21,723 | 0.0127% | ||
| 30/06 | Other | Company | -86,200 | 0.0504% | ||
| 30/06 | Other | Director | -21,723 | 0.0127% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.74% | +3.51% | +51.91% | +726.40% | 15.75B | |
| +1.84% | -0.66% | +59.82% | +92.96% | 54.88B | |
| -4.14% | -8.06% | +58.96% | +118.67% | 54.63B | |
| -2.24% | +3.59% | +17.75% | +477.47% | 25.06B | |
| -1.60% | -6.21% | -18.96% | -15.21% | 23.14B | |
| +2.43% | +1.06% | +42.44% | -1.27% | 19.87B | |
| -3.19% | 0.00% | +35.60% | -26.98% | 17.55B | |
| -6.84% | +2.18% | +195.12% | +357.18% | 16.5B | |
| -1.05% | +1.16% | +25.95% | +194.27% | 14.2B | |
| -4.16% | +1.63% | +70.13% | +142.72% | 12.37B | |
| Average | -1.02% | -0.09% | +53.87% | +206.62% | 25.39B | |
| Weighted average by Cap. | -1.05% | -1.30% | +52.18% | +175.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.73B 3.16B 402M 352M 325M 300M 569M 38.39B 579M 3.88B 1.52B 18.91B 1.51B 1.48B 65.01B | 4.56B 5.28B 673M 589M 543M 502M 952M 64.21B 968M 6.49B 2.55B 31.63B 2.53B 2.47B 109B |
| Net income | -197M -228M -29.04M -25.4M -23.43M -21.64M -41.06M -2.77B -41.75M -280M -110M -1.36B -109M -107M -4.69B | 631M 730M 93.08M 81.41M 75.09M 69.36M 132M 8.88B 134M 897M 352M 4.37B 349M 342M 15.03B |
| Net Debt | -3.1B -3.58B -457M -400M -369M -340M -646M -43.58B -657M -4.4B -1.73B -21.47B -1.72B -1.68B -73.8B | -3.66B -4.23B -539M -472M -435M -402M -762M -51.43B -775M -5.2B -2.04B -25.34B -2.02B -1.98B -87.11B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | HKD 516.50 | +8.74% | 1,750,538 |
| 09/07/26 | HKD 475.00 | -0.92% | 1,251,509 |
| 08/07/26 | HKD 479.40 | -6.73% | 3,511,084 |
| 07/07/26 | HKD 514.00 | -1.81% | 1,292,620 |
| 06/07/26 | HKD 523.50 | +4.91% | 2,620,296 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6990 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition